-
1
المؤلفون: Piotr Rutkowski, Sama Ahsan, Jean-Jacques Grob, Matteo S. Carlino, James R. Anderson, Merrick I. Ross, John M. Kirkwood, Jeffrey E. Gershenwald, Caroline Robert, Jason J. Luke, Nageatte Ibrahim, Charles H. Yoon, Peter Mohr, Georgina V. Long, Alexander M.M. Eggermont, Axel Hauschild, Paolo A. Ascierto, Andrew Poklepovic, Richard A. Scolyer
المصدر: Future Oncology. 16:4429-4438
مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Dermatologic Surgical Procedures, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Placebos, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Adjuvant therapy, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Young adult, Child, Melanoma, Neoplasm Staging, Randomized Controlled Trials as Topic, Cross-Over Studies, business.industry, General Medicine, medicine.disease, Crossover study, Clinical trial, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Adjuvant
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a00dd1a28f82ed3c8216b416ba2d53Test
https://doi.org/10.2217/fon-2019-0666Test -
2
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
3
المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test -
4
المؤلفون: Christian U. Blank, Mario Mandalà, Caroline Robert, Rutger H. T. Koornstra, Shahneen Sandhu, Susana Puig, Piotr Rutkowski, Ralf Gutzmer, Andrew M. Haydon, Andrey Meshcheryakov, Anna Maria Di Giacomo, Clemens Krepler, Victoria Atkinson, Leonel Hernandez-Aya, Adnan Khattak, James Larkin, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Alexander M.M. Eggermont, Georgina V. Long, Michal Kicinski, Dirk Schadendorf, Alexander C.J. van Akkooi, Nageatte Ibrahim, S. Dalle, Paolo A. Ascierto, Stefan Suciu, Rahima Jamal, Sandrine Marreaud, Paul Lorigan
المصدر: Journal of Clinical Oncology, 39, 8, pp. 944-946
Journal of Clinical Oncology, 39, 944-946مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, MEDLINE, Medizin, Pembrolizumab, Adjuvant therapy, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], Text mining, Clinical trials, Internal medicine, Recurrence free survival, Medicine, Staging systems, Risk of relapse, Metastatic relapse, business.industry, Melanoma, Stage at diagnosis, medicine.disease, Clinical trial, Hormonal therapy, pembrolizumab, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c843a2657530330474a766f083b07e20Test
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102657696Test -
5
المؤلفون: Sama Ahsan, Michael A. Postow, Janis M. Taube, Hussein Abdul-Hassan Tawbi, Caroline Robert, Anna C. Pavlick, Richard A. Scolyer, Scott J. Diede, Reinhard Dummer, Georgina V. Long, Michael T. Tetzlaff, Antoni Ribas, Jason J. Z. Liao
المصدر: Regular and young investigator award abstracts.
مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Pembrolizumab, Institutional review board, Discontinuation, Clinical trial, Response Evaluation Criteria in Solid Tumors, Internal medicine, Adjuvant therapy, Medicine, business, Adverse effect, Neoadjuvant therapy
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::82ef96811ba08ac93d1a43925bc712fdTest
https://doi.org/10.1136/jitc-2020-sitc2020.0426Test -
6
المؤلفون: Piotr Rutkowski, Alexander C.J. van Akkooi, Michele Maio, Alfonsus J. M. van den Eertwegh, Christian U. Blank, Nageatte Ibrahim, Adnan Khattak, Paolo A. Ascierto, Rahima Jamal, Ralf Gutzmer, Andrew Haydon, Mikhail Lichinitser, Susana Puig, Victoria Atkinson, Mario Mandalà, Sandrine Marreaud, Caroline Robert, Jean-Jacques Grob, Alexander M.M. Eggermont, Stefan Suciu, Stéphane Dalle, Rutger H. T. Koornstra, Leonel Hernandez-Aya, Shahneen Sandhu, Paul Lorigan, Georgina V. Long, Matteo S. Carlino, James Larkin, Dirk Schadendorf
المساهمون: Universitat de Barcelona, Medical oncology, CCA - Cancer Treatment and quality of life
المصدر: Recercat. Dipósit de la Recerca de Catalunya
instname
The New England Journal of Medicine, 378, 1789-1801
New England Journal of Medicine, 378(19), 1789-1801. Massachussetts Medical Society
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Maio, M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P, Ibrahim, N, Marreaud, S, van Akkooi, A C J, Suciu, S & Robert, C 2018, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma ', New England Journal of Medicine, vol. 378, no. 19, pp. 1789-1801 . https://doi.org/10.1056/NEJMoa1802357Test
Dipòsit Digital de la UB
Universidad de Barcelona
The New England Journal of Medicine, 378, 19, pp. 1789-1801مصطلحات موضوعية: 0301 basic medicine, Male, Skin Neoplasms, Medizin, Pembrolizumab, Kaplan-Meier Estimate, Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Disease-Free Survival, Double-Blind Method, Female, Humans, Infusions, Intravenous, Intention to Treat Analysis, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Survival Rate, Gastroenterology, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Immunologic, Monoclonal, 80 and over, Humanized, Adjuvant treatment of cancer, education.field_of_study, General Medicine, Local, 030220 oncology & carcinogenesis, Intravenous, medicine.drug, Tractament adjuvant del càncer, medicine.medical_specialty, Infusions, Population, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, Adjuvants, education, Survival rate, business.industry, Cancer, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, Cutaneous melanoma, business, Placebos (Medicine)
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae9f22b7acc35569131373f281fa946Test
https://doi.org/10.1056/NEJMoa1802357Test -
7
المؤلفون: Caroline Robert, Alexander M. M. Eggermont
المصدر: Oncoimmunology ISBN: 9783319624303
مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Melanoma, Cancer, Ipilimumab, Immunotherapy, Pembrolizumab, medicine.disease, Radiation therapy, Internal medicine, medicine, Adjuvant therapy, Nivolumab, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::abb1366358ee10a2a388b9b693096ed6Test
https://doi.org/10.1007/978-3-319-62431-0_34Test -
8
المؤلفون: Jeffrey E. Gershenwald, Merrick I. Ross, Nageatte Ibrahim, Charles H. Yoon, Vernon K. Sondak, Jean-Jacques Grob, Piotr Rutkowski, John M. Kirkwood, Alexander M.M. Eggermont, Andrew Poklepovic, Jason J. Luke, Richard A. Scolyer, Georgina V. Long, Sama Ahsan, Peter Mohr, James R. Anderson, Matteo S. Carlino, Caroline Robert, Axel Hauschild, Paolo A. Ascierto
المصدر: Journal of Clinical Oncology. 37:TPS9596-TPS9596
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Pembrolizumab, Placebo, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Stage II melanoma, Adjuvant therapy, Medicine, In patient, Stage III melanoma, business, Adjuvant, 030215 immunology
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::dfd1a33d37748bae5890bfaca892ce80Test
https://doi.org/10.1200/jco.2019.37.15_suppl.tps9596Test -
9
المؤلفون: Jean-Jacques Grob, Peter Mohr, Andrew Poklepovic, Richard A. Scolyer, Jason J. Luke, Vernon K. Sondak, Jeffrey E. Gershenwald, James R. Anderson, Matteo S. Carlino, Caroline Robert, John M. Kirkwood, Nageatte Ibrahim, Charles H. Yoon, Georgina V. Long, Alexander M.M. Eggermont, Sama Ahsan, Axel Hauschild, Paolo A. Ascierto, Merrick I. Ross
المصدر: Journal of Clinical Oncology. 37:TPS145-TPS145
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Pembrolizumab, Placebo, Stage II melanoma, Internal medicine, medicine, Adjuvant therapy, Stage III melanoma, business, Adjuvant
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::12cb82cf6dd4d9636fb43dbb994f2112Test
https://doi.org/10.1200/jco.2019.37.8_suppl.tps145Test -
10
المؤلفون: Alfonsus J. M. van den Eertwegh, Sandrine Marreaud, Veronica M. Rivas, James Larkin, Jean-Jacques Grob, Leonel Hernandez-Aya, Sven Janssen, Susana Puig, Michele Maio, Alexander C.J. van Akkooi, Stéphane Dalle, Rahima Jamal, Matteo S. Carlino, Ralf Gutzmer, Nageatte Ibrahim, Alexander M.M. Eggermont, Mario Mandalà, Dirk Schadendorf, Stefan Suciu, Piotr Rutkowski, Rutger H. T. Koornstra, Andrew Haydon, Georgina V. Long, Mikhail Lichinitser, Caroline Robert, Shahneen Sandhu, Paolo A. Ascierto, Adnan Khattak, Victoria Atkinson, Christian U. Blank
المصدر: Cancer Research. 78:CT001-CT001
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, education.field_of_study, business.industry, Hazard ratio, Population, Ipilimumab, Pembrolizumab, Interim analysis, Placebo, Gastroenterology, Oncology, Internal medicine, medicine, Adjuvant therapy, Nivolumab, business, education, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::93d5e0e9ed0f65eb2027f40605f571efTest
https://doi.org/10.1158/1538-7445.am2018-ct001Test